Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AES 2022 | BOOST: assessing the value of brain tissue oxygenation monitoring to improve TBI outcomes

Brain tissue oxygenation (PbtO2) is often measured in critical care settings, as low PbtO2 has been associated with poor neurologic recovery. However, there is very little high-quality evidence to support the value of PbtO2 guided-therapy on patient outcomes. Ramon Diaz-Arrastia, MD, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses his work aiming to assess the use of brain tissue oxygenation monitoring in patients with severe traumatic brain injury (TBI). Early findings from a Phase II study of 120 patients demonstrated a promising trend towards improved neurologic outcomes in patients that underwent PbtO2 monitoring. These data led to the establishment of the ongoing BOOST study: Brain Oxygen Optimization in Severe TBI (NCT03754114). Around half of the 1000-person goal have been enrolled to date. Once enrolled, patients are randomized to receive a treatment protocol based on standard monitoring alone (intracranial pressure monitoring) or PbtO2 guided therapy. The trial aims to assess if PbtO2 monitoring can reduce the burden of cerebral hypoxia and thus, improve functional outcomes. This interview took place at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, TN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.